Tesamorelin
What to know about Tesamorelin
Tesamorelin is a stabilized 44-amino-acid GHRH analogue with a licensed U.S. formulation for a narrow, labelled use.
- How it may work
- It activates pituitary GHRH receptors, increasing pulsatile growth hormone and downstream IGF-1 rather than supplying growth hormone directly.
- What research found
- Randomized trials in adults with HIV-associated abdominal fat accumulation found lower visceral-fat measurements, with no comparable reduction in subcutaneous abdominal fat.
- What is not settled
- Licensed labeling includes contraindications and warnings involving active malignancy, pituitary-axis disruption, elevated IGF-1, glucose intolerance, fluid retention, and injection reactions.
- Research and product status
- Tesamorelin has a licensed U.S. product for a specific HIV-associated indication; that does not establish general weight-loss use.
Research reference
- Research amount range
- 1–2 mg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Reported timing context
- Commonly once daily; evening dosing is frequently discussed.
- What people report
- Studied over months for its licensed indication; community timelines run in weeks.
- Model accumulation timescale
- ~3 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- 12+ weeks
- Reported break context
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Pivotal studies measured visceral-fat change at 26 weeks; continued exposure was studied to 52 weeks. The measured result applies to the licensed context and is not a first-week visual-change promise.
- When to assess
- The label says to evaluate visceral-fat response periodically; trials used CT-based endpoints at 26 weeks. Waist or appearance alone is not the same measurement, and the studied context matters.
- Conditions and limitations
- The evidence used daily subcutaneous administration in a defined population. It does not establish a special time of day, fasting window, or stacking partner as required for the measured result.
- When to stop
- The current label and prescriber govern continuation. Trial extensions found that visceral fat reaccumulated after discontinuation, so a short self-directed cycle is not supported by that evidence.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Tesamorelin alongside other compounds or medicines.
Key properties
- Formula
- C221H366N72O67S
- Mol. weight
- 5,135.9 Da
- CAS
- 218949-48-5
- PubChem CID
- 16137828
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Vial arithmetic
Published research contexts for Tesamorelin describe 1–2 mg per administration. Descriptive only, not a recommendation.
Research schedule reference
Reported schedule context for Tesamorelin; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Typical blockA stabilised GHRH analog studied at about 2 mg daily. | 1–2 mg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Tesamorelin visceral-fat study (Falutz et al., NEJM 2007)2 mg daily reduced visceral adipose tissue in research participants.